Dr.

Reddy's Laboratories
Dr. Reddy's Laboratories (Dr. Reddy's) was incorporated in India by Dr. K Anji Reddy in 1984. The

company went public in 1985 and was listed on the Indian Stock Exchanges in 1986.

The company acquired Benzex Laboratories and expanded its Bulk Actives business in 1988. By

1990, Dr. Reddy's exported Norfloxacin and Ciprofloxacin to Europe and Far East. In 1991, it began

to export its products to Russia. Dr. Reddy's Research Foundation was established and became

operational in 1993.

In 2000, the company merged with Cheminor Drugs. In the same year, it also acquired American

Remedies. Also in 2000, Reddy US Therapeutics, a wholly-owned subsidiary, was also launched in

the US.

Dr. Reddy's was listed on the New York Stock Exchange in 2001.

The company made its first overseas acquisition of BMS Laboratories Limited and Meridian

Healthcare, UK in 2002. In the following year, the company signed an agreement with PLIVA, a

global pharmaceuticals company based in Zagreb, Croatia, covering development and marketing

for eleven oncology products.

In 2004, the company entered into a definitive agreement with Bangalore based Stumpp, Schuele

& Somappa (SSS) for the sale of its wholly owned subsidiary, Compact Electric Limited.

Dr. Reddy's entered into a definitive agreement to acquire Roche’s API business at the manufacturing

site in Cuernavaca, Mexico in 2005. In the same year, Dr. Reddy's and ICICI Venture announced a

$56 million-partnership for the commercialization of ANDAs (Abbreviated New Drug Applications).

The company acquired betapharm Group, a generic pharmaceuticals company in Germany, for

E480 million in 2006. In the same year, Dr. Reddy’s and Torrent Pharmaceuticals concluded an

agreement for exclusive commercialization of two of Torrent’s brands in Russia, viz. Listril (Lisinopril)

and Listril Plus (Lisinopril HCTZ), both of which are cardiovascular drugs used in the treatment of

high blood pressure.

In 2007, Dr. Reddy’s expanded its presence in Africa and opened its 40th overseas office in Lagos,

Nigeria in partnership with Phillips Pharmaceuticals. In the same year, US Food and Drug

Administration (FDA) granted final approval for the company’s abbreviated new drug application

(ANDA) for Ranitidine (Zantac) 150mg tablet (Over-the-Counter). Also in 2007, Sygnis and Dr.

Reddy's entered into an exclusive 10 year agreement for the supply of the active ingredient AX200,

a biological molecule in development by Sygnis for the treatment of Stroke and other

neurodegenerative disorders.